Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients

2015 ◽  
Vol 21 (3) ◽  
pp. 675-687 ◽  
Author(s):  
Bibhu Ranjan Das ◽  
Sangeet Bhaumik ◽  
Firoz Ahmad ◽  
Aziz Mandsaurwala ◽  
Heena Satam
Keyword(s):  
Distribution Pattern ◽  
Frequency Distribution ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Gene Mutations ◽  
Small Cell ◽  
Small Cell Lung ◽  
Kras Gene ◽  
Cell Lung Carcinoma

Relationship between driver gene mutations, their relative protein expressions and survival in non‐small cell lung carcinoma in Macao

2017 ◽  
Vol 12 (4) ◽  
pp. 1416-1423
Author(s):  
Kin Iong Chan ◽  
Hong Ting Vong ◽  
Lai Fong Sin ◽  
Yuk Ching Yip ◽  
Xue Yun Zhong ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Gene Mutations ◽  
Small Cell ◽  
Driver Gene ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Protein Expressions

scholarly journals Analysis of the effect of NEKs on the prognosis of patients with Non-small-cell lung carcinoma based on bioinformatics

2021 ◽  
Author(s):  
MENGXIA YANG ◽  
YIKUN GUO ◽  
XIAOFEI GUO ◽  
YUN MAO ◽  
SHIJIE ZHU ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Gene Mutations ◽  
Tumor Stage ◽  
Good Prognosis ◽  
Small Cell ◽  
High Expression ◽  
Clinicopathological Parameters ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

Abstract NEKs are proteins that are involved in various cell processes and play important roles in the formation and development of cancer. However, few studies have examined the role of NEKs in the development of non-small-cell lung carcinoma (NSCLC). To address this problem, the Oncomine, UALCAN, and the Human Protein Atlas databases were used to analyze differential NEK expression and its clinicopathological parameters, while the Kaplan-Meier, cBioPortal, GEPIA, and DAVID databases were used to analyze survival, gene mutations, similar genes, and biological enrichments. The rate of NEK family gene mutation was high (>50%) in patients with NSCLC, in which NEK2/4/6/8/ was overexpressed and significantly correlated with tumor stage and nodal metastasis status. In addition, the high expression of NEK2/3mRNA was significantly associated with poor prognosis in patients with NSCLC, while high expression of NEK1/4/6/7/8/9/10/11mRNA was associated with good prognosis. In summary, these results suggest that NEK2/4/6/8 may be a potential prognostic biomarker for the survival of patients with NSCLC.

Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation

1995 ◽  
Vol 41 (4) ◽  
pp. 537-543 ◽  
Author(s):  
K Aoyagi ◽  
Y Miyake ◽  
K Urakami ◽  
T Kashiwakuma ◽  
A Hasegawa ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Healthy Subjects ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Analytical Recovery ◽  
Highly Sensitive ◽  
Reliable Marker

Abstract Previously, using recombinant human progastrin-releasing peptide (ProGRP)(31-98), we developed a RIA for ProGRP(31-98) and demonstrated that the determination of serum ProGRP(31-98) was a reliable marker for small-cell lung carcinoma (SCLC) (Miyake et al., Cancer Res 1994;54:2136-40). Aiming for a more convenient assay system, we have now developed and evaluated a highly sensitive and specific ELISA for ProGRP(31-98). Only 50 microL of nonextracted serum is needed, and results are obtained in only 2 h. Intraassay and between-day CVs were 1.7-4.6% and 4.2-6.8%, respectively. The log-log calibration curve was linear to 1000 ng/L, and analytical recovery was 91.5-108.7%. The detection limit of this assay, 1.9 ng/L, means that basal concentrations of ProGRP(31-98) were detectable in all healthy subjects. The cutoff value, based on the mean + 3 SD of concentrations in 247 healthy subjects, was set to 45.1 ng/L. Serum concentrations exceeded this value in 18 of 25 SCLC patients, similar to the frequency of increased values found by RIA previously. In contrast, the frequency of increased serum ProGRP(31-98) in patients with nonmalignant pulmonary diseases or non-SCLC was quite low: 0% and 5.0%, respectively. Such results may justify a clinical trial for evaluating this ELISA for the diagnosis and monitoring of SCLC patients.

Clinical value of an amplified electrophoretic determination of enolase isoenzymes in small cell lung carcinoma patients

1989 ◽  
Vol 49 (1) ◽  
pp. 33-42 ◽  
Author(s):  
C. Batandier ◽  
E. Brambilla ◽  
H. N Agy-Mignotte ◽  
F. Laporte ◽  
M. Jacrot ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Clinical Value ◽  
Cell Lung Carcinoma

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document